Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma

Mohammed A. Aljama, M. Hasib Sidiqi, Arjun Lakshman, Angela Dispenzieri, Dragan Jevremovic, Morie Gertz, Martha Lacy, Francis K. Buadi, David M Dingli, Eli Muchtar, Amie L. Fonder, Suzanne R. Hayman, Miriam A. Hobbs, Wilson Gonsalves, Rahma Warsame, Taxiarchis Kourelis, Yi Lisa Hwa, Prashant Kapoor, Nelson Leung, Ronald S. GoRobert A. Kyle, S Vincent Rajkumar, Shaji K Kumar

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The plasma cell proliferative index (PCPI), determined by a slide technique or by flow cytometry, detects cells in the S phase of the cell cycle and is a useful prognostic tool in patients with plasma cell disorders such as multiple myeloma and amyloidosis. We conducted a retrospective review analyzing the prognostic effect of PCPI in 306 patients with smoldering multiple myeloma (SMM). Seventy-nine (26%) patients had an elevated PCPI (>0.5). An elevated PCPI predicted an inferior time to progression (median, 3.0 vs 7.1 years for those with a low PCPI; P = .0004). Within 24 months, the progression rate was significantly higher for patients with an elevated PCPI (49% vs. 20%; P < .0001). PCPI is a valuable tool in risk stratifying patients with SMM and identifies patients with earlier progression who may benefit from closer follow-up and consideration of early intervention trials.

Original languageEnglish (US)
Pages (from-to)3149-3154
Number of pages6
JournalBlood advances
Volume2
Issue number22
DOIs
StatePublished - Nov 27 2018
Externally publishedYes

Fingerprint

Plasma Cells
Multiple Myeloma
Amyloidosis
S Phase
Cell Cycle
Flow Cytometry

Cite this

Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma. / Aljama, Mohammed A.; Sidiqi, M. Hasib; Lakshman, Arjun; Dispenzieri, Angela; Jevremovic, Dragan; Gertz, Morie; Lacy, Martha; Buadi, Francis K.; Dingli, David M; Muchtar, Eli; Fonder, Amie L.; Hayman, Suzanne R.; Hobbs, Miriam A.; Gonsalves, Wilson; Warsame, Rahma; Kourelis, Taxiarchis; Hwa, Yi Lisa; Kapoor, Prashant; Leung, Nelson; Go, Ronald S.; Kyle, Robert A.; Rajkumar, S Vincent; Kumar, Shaji K.

In: Blood advances, Vol. 2, No. 22, 27.11.2018, p. 3149-3154.

Research output: Contribution to journalArticle

Aljama, Mohammed A. ; Sidiqi, M. Hasib ; Lakshman, Arjun ; Dispenzieri, Angela ; Jevremovic, Dragan ; Gertz, Morie ; Lacy, Martha ; Buadi, Francis K. ; Dingli, David M ; Muchtar, Eli ; Fonder, Amie L. ; Hayman, Suzanne R. ; Hobbs, Miriam A. ; Gonsalves, Wilson ; Warsame, Rahma ; Kourelis, Taxiarchis ; Hwa, Yi Lisa ; Kapoor, Prashant ; Leung, Nelson ; Go, Ronald S. ; Kyle, Robert A. ; Rajkumar, S Vincent ; Kumar, Shaji K. / Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma. In: Blood advances. 2018 ; Vol. 2, No. 22. pp. 3149-3154.
@article{41f57bf9ba984aaa8496b428245c656a,
title = "Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma",
abstract = "The plasma cell proliferative index (PCPI), determined by a slide technique or by flow cytometry, detects cells in the S phase of the cell cycle and is a useful prognostic tool in patients with plasma cell disorders such as multiple myeloma and amyloidosis. We conducted a retrospective review analyzing the prognostic effect of PCPI in 306 patients with smoldering multiple myeloma (SMM). Seventy-nine (26{\%}) patients had an elevated PCPI (>0.5). An elevated PCPI predicted an inferior time to progression (median, 3.0 vs 7.1 years for those with a low PCPI; P = .0004). Within 24 months, the progression rate was significantly higher for patients with an elevated PCPI (49{\%} vs. 20{\%}; P < .0001). PCPI is a valuable tool in risk stratifying patients with SMM and identifies patients with earlier progression who may benefit from closer follow-up and consideration of early intervention trials.",
author = "Aljama, {Mohammed A.} and Sidiqi, {M. Hasib} and Arjun Lakshman and Angela Dispenzieri and Dragan Jevremovic and Morie Gertz and Martha Lacy and Buadi, {Francis K.} and Dingli, {David M} and Eli Muchtar and Fonder, {Amie L.} and Hayman, {Suzanne R.} and Hobbs, {Miriam A.} and Wilson Gonsalves and Rahma Warsame and Taxiarchis Kourelis and Hwa, {Yi Lisa} and Prashant Kapoor and Nelson Leung and Go, {Ronald S.} and Kyle, {Robert A.} and Rajkumar, {S Vincent} and Kumar, {Shaji K}",
year = "2018",
month = "11",
day = "27",
doi = "10.1182/bloodadvances.2018024794",
language = "English (US)",
volume = "2",
pages = "3149--3154",
journal = "Blood advances",
issn = "2473-9529",
publisher = "American Society of Hematology",
number = "22",

}

TY - JOUR

T1 - Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma

AU - Aljama, Mohammed A.

AU - Sidiqi, M. Hasib

AU - Lakshman, Arjun

AU - Dispenzieri, Angela

AU - Jevremovic, Dragan

AU - Gertz, Morie

AU - Lacy, Martha

AU - Buadi, Francis K.

AU - Dingli, David M

AU - Muchtar, Eli

AU - Fonder, Amie L.

AU - Hayman, Suzanne R.

AU - Hobbs, Miriam A.

AU - Gonsalves, Wilson

AU - Warsame, Rahma

AU - Kourelis, Taxiarchis

AU - Hwa, Yi Lisa

AU - Kapoor, Prashant

AU - Leung, Nelson

AU - Go, Ronald S.

AU - Kyle, Robert A.

AU - Rajkumar, S Vincent

AU - Kumar, Shaji K

PY - 2018/11/27

Y1 - 2018/11/27

N2 - The plasma cell proliferative index (PCPI), determined by a slide technique or by flow cytometry, detects cells in the S phase of the cell cycle and is a useful prognostic tool in patients with plasma cell disorders such as multiple myeloma and amyloidosis. We conducted a retrospective review analyzing the prognostic effect of PCPI in 306 patients with smoldering multiple myeloma (SMM). Seventy-nine (26%) patients had an elevated PCPI (>0.5). An elevated PCPI predicted an inferior time to progression (median, 3.0 vs 7.1 years for those with a low PCPI; P = .0004). Within 24 months, the progression rate was significantly higher for patients with an elevated PCPI (49% vs. 20%; P < .0001). PCPI is a valuable tool in risk stratifying patients with SMM and identifies patients with earlier progression who may benefit from closer follow-up and consideration of early intervention trials.

AB - The plasma cell proliferative index (PCPI), determined by a slide technique or by flow cytometry, detects cells in the S phase of the cell cycle and is a useful prognostic tool in patients with plasma cell disorders such as multiple myeloma and amyloidosis. We conducted a retrospective review analyzing the prognostic effect of PCPI in 306 patients with smoldering multiple myeloma (SMM). Seventy-nine (26%) patients had an elevated PCPI (>0.5). An elevated PCPI predicted an inferior time to progression (median, 3.0 vs 7.1 years for those with a low PCPI; P = .0004). Within 24 months, the progression rate was significantly higher for patients with an elevated PCPI (49% vs. 20%; P < .0001). PCPI is a valuable tool in risk stratifying patients with SMM and identifies patients with earlier progression who may benefit from closer follow-up and consideration of early intervention trials.

UR - http://www.scopus.com/inward/record.url?scp=85056940469&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056940469&partnerID=8YFLogxK

U2 - 10.1182/bloodadvances.2018024794

DO - 10.1182/bloodadvances.2018024794

M3 - Article

C2 - 30463914

AN - SCOPUS:85056940469

VL - 2

SP - 3149

EP - 3154

JO - Blood advances

JF - Blood advances

SN - 2473-9529

IS - 22

ER -